A pharmacokinetic evaluation of pravastatin in middle-aged and elderly volunteers

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 23, Issue 1, 1998, Pages 13-18

  Sigurbjornsson S ^a,b   Kjartansdottir T ^a   Jóhannsson, Magnús ^a   Kristinsson, J ^a   Sigurdsson, G ^b  

^a UNIVERSITY OF ICELAND   (Iceland)

^b Reykjavik City Hospital   (Iceland)

Author keywords

Analysis; HPLC; Pharmacokinetics; Pravastatin

Indexed keywords

HYPOCHOLESTEROLEMIC AGENT; PRAVASTATIN;

ADULT; AGED; ANALYTICAL EQUIPMENT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG STRUCTURE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; SOLID PHASE EXTRACTION; VOLUNTEER;

EID: 2642701748     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03189821     Document Type: Article

References (15)

1. Ende A., Kuroda M., Tsyhuta Y. (1976) : ML-236A, ML-236B and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinum. J. Antibiot. (Tokyo), 29, 1346-1348.
2. Alberts A.W. (1988) : Discovery, biochemistry and biology of lovastatin. Am. J. Cardiol., 62, 10J-15J.
3. Everett D.W., Chando T.J., Didonato G.C., Singhvi S.M., Pan H.Y., Weinstein S.H. (1991) : Biotransformation of pravastatin sodium in humans. Drug. Metab. Dispos., 19, 740-748.
4. Pan H.Y., Funke P.T., Willard D.A., McKinstry D.N. (1989) : Pharmacokinetics, pharmacodynamics and safety of pravastatin sodium, a potent inhibitor of HMG-CoA reductase, in healthy volunteers. International. Congress Symposium Series no 162. London: Royal Society of Medicine, 9-21.
5. Pan H.Y. (1991) : Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase. Eur. J. Clin. Pharmacol., 40 (Suppl. 1), S15-S18.
6. Pan H.Y., Waclawski A.P., Funke P.T., Whigan D. (1993) : Pharmacokinetics of pravastatin in elderly versus young men and women. Ann. Pharmacother., 27, 1029-1033.
7. Kjartansdóttir T., Kristinsson J., Kristjansson S. (1992) : Determination of pravastatin in serum by high-performance liquid chromatography and solid-phase extraction. Scand. J. Clin. Lab. Invest., suppl. 211, 52, 101.
8. Funke P.T., Ivashkiv E., Arnold M.E., Cohen A.I. (1989) : Determination of pravastatin sodium and its major metabolites in human serum/plasma by capillary gas chromatography/negative ion chemical ionisation mass spectrometry. Biomed. Environ. Mass Spectrom., 18, 904-909.
9. Morris M.J., Gilbert J.D., Hsie J.Y., Matuszewski B.K., Ramjit H.G., Bayne W.F. (1993) : Determination of the HMG-CoA reductase inhibitors simvastatin, lovas tatin and pravastatin in plasma by gas chromatography/chemical ionisation mass spectrometry. Biomed. Environ. Mass Spectrom., 22, 1-8.
10. Pan H.Y., DeVault A.R., Swites B.J. et al. (1990) : Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia. Clin. Pharmacol. Ther., 48, 201-207.
11. Pan H.Y., Willard D.A., Funke P.T., McKinstry D.N. (1987) : The clinical pharmacology of SQ 3100 (CS 514) in healthy subjects. Paoletti R. et al.(Eds). Drugs Affecting Lipid Metabolism. Heidelberg: Springer.
12. Vega G.L., Krauss R.M., Grundy S.M. (1990) : Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B-containing lipoproteins. J. Intern. Med, 227, 81-94.
13. Franceschini G., Sirtori M., Vaccarino V., Gianfranceschi G., Chiesa G., Sirtori C.R. (1989) : Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia. J. Lab. Clin. Med., 114, 250-259.
14. Johnson B. F., LaBelle P., Wilson J., Allan J., Zupkis R.V., Ronca P.D. (1990) ; Effects of lovastatin in diabetic patients treated with chlorpropamide. Clin. Pharmacol. Ther., 48, 467-472.
15. Saito Y., Goto Y., Nakaya N. et al. (1988) : Dose-dependent hypolipidemic effect of an inhibitor of HMG-CoA reductase, pravastatin (CS-514), in hypercholesterolemic subjects. A double blind test. Atherosclerosis, 72, 205-211.